Skip to main content

Table 2 Descriptive statistics for %∆CDAI, ACR-N, and ∆HAQ-DI at month 12

From: Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate: a post hoc analysis of data from ORAL Strategy

  CDAI ACR-N HAQ-DI
Na Baseline,
mean (SE)
%∆ at month 12,
mean (SE)
Na At month 12,
mean (SE)
Na Baseline,
mean (SE)
∆ at month 12,
mean (SE)
Tofacitinib monotherapy 319 38.7 (0.7)  − 65.3 (1.8) 320 32.2 (6.0) 320 1.59 (0.04)  − 0.63 (0.04)
Tofacitinib + MTX 309 40.5 (0.7)  − 74.0 (1.2) 310 49.1 (2.1) 311 1.57 (0.04)  − 0.67 (0.04)
ADA + MTX 312 38.3 (0.8)  − 72.2 (1.4) 314 45.1 (2.8) 313 1.55 (0.04)  − 0.67 (0.03)
  1. , change from baseline; ACR-N, American College of Rheumatology response rate, where ACR is the percentage improvement from baseline in American College of Rheumatology components, and N represents the minimum percentage achieved by each patient; ADA, adalimumab; CDAI, Clinical Disease Activity Index; HAQ-DI, Health Assessment Questionnaire-Disability Index; MTX, methotrexate; SE, standard error
  2. aNumber of patients with month 12 data for ≥ 1 efficacy endpoint